MTOR and neoplasm: In contrast, the average tumor volumes of the [177Lu]Lu-DOTA-CCK2R-dimer, mTOR inhibitor, and combined treatment groups were significantly smaller (p < 0.05) at 302.72 ± 100.12 mm3, 197.63 ± 40.92 mm3, and 139.10 ± 39.86 mm3, respectively.